In April’s issue of Pharma Times Magazine, partner Cullen Taylor explores how new machine learning technologies may have far-reaching, unexpected effects on IP and patent law. Cullen’s article looks at how AI is likely to accelerate the process of developing drugs and identifying patients who can benefit from them. It outlines patentability challenges for policy makers as well
Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal Circuit and holding that, when a patent holder sells a product, it exhausts all of its patent rights in the product, regardless of certain restrictions that the patent holder sought to impose on further resale.
Industry sources estimate that more than $4 billion worth of deals in digital health have been signed globally this year so far, as pharmaceutical manufacturers look for “beyond the pill” solutions to medical problems, health care providers seek more efficient means to monitor their patients’ wellbeing, and technology companies aim to commercialize their products and